Vaccinex raises ~$2.96M via private placement of 7.9M shares at $0.37428

VACCINEX, INC.

Sold 7,908,516 shares at $0.37428/share for $2.96M gross proceeds; closed May 15, 2023.
Proceeds to fund pepinemab development in cancer/neurodegenerative disease and working capital.
FCMI Parent Co., controlled by chairman Albert D. Friedberg, participated in the offering.
Shares unregistered; exempt under Rule 506 and Section 4(a)(2); registration rights granted to other investors.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

VACCINEX, INC. entered into Stock Purchase Agreement with certain accredited investors valued at approximately $2.96 million (effective 2023-05-12).

Action: entry
Agreement: equity purchase
Counterparty: certain accredited investors
Value: approximately $2.96 million
Effective: 2023-05-12

Exact text from the filing

On May 12, 2023, Vaccinex, Inc. (the “Company”) entered into a stock purchase agreement (the “Stock Purchase Agreement”) pursuant to which the Company agreed to issue and sell 7,908,516 shares of common stock of the Company (the “Shares”) at a purchase price of $0.37428 per Share for aggregate gross proceeds of approximately $2.96 million.

View on SEC.gov

Browse all material agreements →

VACCINEX, INC. filing history →

Source: SEC EDGAR

accession 0001193125-23-145153

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.